Charles River Laboratories (CRL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $16.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Charles River Laboratories (CRL) Stock Forecast
Analysts expect Charles River Laboratories (CRL) to earn $11.47 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.95B. Of 17 analysts, 14 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.06, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 17.6% |
| Buy | 11 | 64.7% |
| Hold | 2 | 11.8% |
| Sell | 1 | 5.9% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 13.1% and revenue estimates rise 2.8%.
- Fiscal year ending Dec 31, 2026
- $11.47
- EPS consensus, revenue $3.95B
- Fiscal year ending Dec 31, 2027
- $12.97
- EPS consensus, revenue $4.06B
- Next report
- Feb 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $11.47 | $11.36 to $11.62 | 15 | $3.95B | $3.94B to $4.00B | 12 |
| Dec 31, 2027 | $12.97 | $12.36 to $13.63 | 15 | $4.06B | $4.01B to $4.13B | 12 |
Quarterly Estimates
The EPS consensus falls from $3.35 for the quarter ending Dec 31, 2026 to $2.87 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.35 | $3.16 to $3.56 | 15 | $979.02M | $923.26M to $1.06B | 15 |
| Mar 31, 2027 | $2.87 | $2.48 to $3.13 | 7 | $991.30M | $969.20M to $1.02B | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 21 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 14 | 0 |
| Fiscal year ending Dec 31, 2027 | 7 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.3% from $11.32.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $11.47 | $11.38 | $11.37 | $11.32 | $11.32 | +1.4% |
| Fiscal year ending Dec 31, 2027 | $12.97 | $12.75 | $12.77 | $12.69 | $12.69 | +2.2% |
| Quarter ending Mar 31, 2027 | $2.87 | $2.86 | $2.84 | $2.79 | $2.79 | +2.7% |
Frequently Asked Questions About CRL
What is the CRL stock forecast?
Consensus analyst estimates put Charles River Laboratories's EPS at $11.47 for the fiscal year ending Dec 31, 2026, on revenue of $3.95B. The consensus rating from 17 analysts is Buy.
How do analysts rate CRL stock?
Of 17 analysts covering Charles River Laboratories, 3 rate it Strong Buy, 11 Buy, 2 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $11.47, with estimates from $11.36 to $11.62 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $12.97, with estimates from $12.36 to $13.63 from 15 analysts.
What revenue do analysts expect from Charles River Laboratories next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.95B, with estimates from $3.94B to $4.00B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.06B, with estimates from $4.01B to $4.13B.
How many analysts cover CRL?
17 analysts rate Charles River Laboratories stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts